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Mis-regulation of the alternative splicing factor muscleblind-like I (MBNL 1) plays a 
significant role in the disease myotonic dystrophy (OM). MBNL 1 regulates alternative 
splicing of genes involved in development of skeletal muscle, heart and the central 
nervous system. In myotonic dystrophy the lack of properly localized MBNL 1 leads to 
mis-splicing of many pre-mRNAs. One of the mis-spliced pre-mRNAs is the MBNLJ 
pre-mRNA that codes for the MBNL 1 protein (an auto-regulated event). Specifically, 
the mis-splicing is aberrant inclusion of exon 5 in the MBNLJ pre-mRNA. Previous 
work has shown that intron 4 of the MBNLJ gene is highly conserved and contains 
multiple MBNLI binding sites. It has been shown that a 90-nucleotide region within 
intron 4 is necessary for regulation by MBNL 1. This study investigates the sensitivity of 
the auto-regulated MBNLJ splicing event by generating MBNL 1 dose-response curves 
using HEK293 cells with an inducible MBNL 1 expression system. Coupling this 
expression system with MBNLJ constructs containing deletions of various MBNLI 
iii  
binding sites within the important 90 nucleotide regulation region, it was shown that a 
single central MBNL1 site was fundamentally more important that other sites for 
splicing regulation.  
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Background: The Central Dogma of Molecular Biology 
 The central dogma of molecular biology describes how genetic information 
given by DNA results in protein in biological systems. The ideas of the central dogma 
of molecular biology are all based on experimental evidence and represent a synthesis 
of the knowledge gained by many scientists over time. The term dogma was used in 
order to reflect how fundamental the core idea is to modern scientists.  
 
DNA is the hereditary material in all organisms, including humans. DNA is 
packaged in structures called chromosomes, which are found in the nucleus of a cell. 
The information in DNA is given by a code that is made up on four chemical bases: 
adenine (A), cytosine (C), guanine (G) and thymine (T). The human genome consists of 
about 3 billion of these bases. Of these bases about 99 percent are the same in all 
humans. The order or sequence of these bases is what gives the information necessary 
for proper growth and function of an organism.  
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DNA bases pair with one another: A with T and C with G to form what are 
called base pairs. Each of the chemical bases is attached to a sugar and phosphate 
molecule. The base, sugar, phosphate unit is called a nucleotide and these nucleotides 
are arranged in two long anti-parallel strands (meaning that they have opposite polarity) 
that form a double-helix. The asymmetric ends of DNA are called 5’ and 3’ because the 
5’ end has a terminal phosphate group while the 3’ has a terminal hydroxyl group. 
 While DNA is the total hereditary material, its basic physical unit is called a 
gene. Gene expression results in the formation of a protein that has a specific role in the 
cell. The first step of gene expression occurs when the DNA of a gene is copied into 
ribonucleic acid (RNA) through a process called transcription (Figure 1). In this process 
a complementary anti-parallel strand of RNA is formed which includes the same base 
pairs as DNA except that instead of thymine (T), RNA includes uracil (U). This 
transcript of RNA is termed pre-messenger RNA or pre-mRNA. This pre-mRNA 
undergoes different types of processing within the nucleus and is then moved to the 
cytoplasm. Here, the mRNA is translated into protein by the ribosome. 
 At it’s most basic level the central dogma relates how a gene becomes a protein. 
Within this context, however, there are small changes that can effectively tune how the 
flow of genetic information works. For example, at any one time only a small portion of 
the DNA contained in any cell is being actively transcribed. Furthermore, the genes that 
are transcribed contain intervening sequences that provide for further change in the gene 
product (alternative splicing). This can reflect how different protein isoforms are being 
expressed either at different levels or in different tissues. At any level of the flow chart 
shown in Figure 1, expression of protein (and the form of the protein) can be controlled. 
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This study aims to understanding how protein isoform levels are varied at the 
alternative splicing level. 
Background: Pre-mRNA processing 
 After the initial transcript is made from a gene (pre-mRNA) it must undergo 
processing in the nucleus. This includes the addition of a 5’ cap, splicing, editing, and 
polyadenine tail (Poly(A) tail) at the 3’ end. A typical mature RNA (mRNA) contains 
the 5’ cap, 5’ untranslated region (UTR), coding sequence, 3’ UTR, and Poly(A) tail 
(Figure 2, 1).  
 Both the 5’ UTR and 3’ UTR are non-coding (not translated by the ribosome 
into protein) but are necessary for many reasons. They are important for mRNA 
localization, stability, and translational efficiency by the ribosome. Proteins can bind to 
either of the UTRs and either promote or inhibit translation. 
The 5’ cap is a modified guanine nucleotide and critical for proper attachment of 
the mRNA to the ribosome. It also functions as a protection from exonucleases. The 3’ 
Poly(A) tail promotes export from the nucleus and promotes translation. Like the 5’ 
cap, it also serves to protect the mRNA from degradation. 
 The mature coding sequence is formed through process known as splicing. In 
this process, introns are excised and exons are ligated together to form the mature RNA. 
This occurs because large parts of any gene are non-coding (introns). Exons are any 
sequence needed for encoding the final protein product. Alternative splicing allows for 
one gene to produce more than one type of RNA, which can encode for multiple 
different proteins, thus increasing proteomic diversity. About 92-94% of human multi-
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exon genes are alternatively spliced (2). Of these at least 85% have a minor isoform that 
is expressed at a frequency of 15% (3). 
 
 Splicing of pre-mRNA is performed by an RNA and protein complex that is 
known as the spliceosome (2). Different trans-acting proteins known as repressors and 
activators, cis-acting regulatory sites (enhancers and silencers) and other RNA features 
such as secondary structure determine how splicing is regulated and how it will occur 
based on the cellular environment. 
 Pre-mRNA splicing is dependent upon the recognition of four canonical motifs 
(5’ splice site, branch point sequence, polypyrimidine tract (PY tract), and the 3’ splice 
site). Both the 3’ splice site and 5’ splice site have consensus sequences but these do not 
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contain enough information to always define which exons must be included or 
excluded. For this reason non-canonical splicing signals are also important as they act to 
recruit the spliceosome and other splicing factors (4).  
 The spliceosome itself is a large, complex, and not entirely understood 
molecular machine made of both small RNAs and proteins. The human splicing 
machinery contains many small nuclear RNAs (U1, U2, U4, U5, and U6) and more than 
300 proteins (5). Once the intron is recognized by the spliceosome, splicing occurs in 
two straight forward steps. First the 2’ hydroxyl of the branchpoint adenosine attacks 
the 5’ splice junction which results in breakage of that phosphodiester bond. 
Simultaneously, a 2’-5’ phosphodiester linkage between the branch point and the 5’ 
terminal nucleotide of the intron is formed. At the end of the first step the intron is the 
form of a lariat. In the next step the released 3’ hydroxyl of the 5’ exon attacks the 3’ 
splice junction breaking the phosphodiester bond while forming a new phosphodiester 
bond between the 5’ exon and the 3’ exon. The intron is then released in the lariat form 
(6). 
There are many different types of alternative splicing, which include mutually 
exclusive exons, alternative 5’ splice sites, alternative 3’ acceptor sites, intron retention, 
and cassette exon skipping (Figure 1). Exon skipping is the most common type of 
splicing in mammals (7). In exon skipping, an exon may either be excised out of the 
pre-mRNA or retained. Often whether or not an exon is included depends on the stage 
of development or whether or not certain regulatory factors are available. This is the 
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type of splicing focused on in the present study. 
 
Background: Human Genetic Diseases 
 Genes code for proteins, which serve a many functions in the cell. When a 
mutation occurs in the DNA of a gene, human genetic diseases arise. The human 
genome contains between 20,000 to 25,000 genes. Single-gene diseases are the result of 
a mutation in just one gene. 
 Humans have 23 pairs of chromosomes. One chromosome of each pair is 
inherited from each parent. Each member of the homologous pair has the same genetic 
material and is located at the same physical positions on the chromosome. Each pair of 
chromosomes carries specific genes and of those genes can be slightly different, which 
is defined as alleles. If both parents contribute the same allele to the offspring then the 
offspring is homozygous for that allele. If the parents contribute different alleles then 
the offspring is a heterozygote.  
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 The interaction between the two alleles can be defined as either recessive or 
dominant. Which ever parent the heterozygous offspring is phenotypically identical to is 
the parent that contributed the dominant allele. Thus diseases can be either dominant 
(inherited from one parent) or recessive (must be inherited from both) and either 
autosomal (not on a sex chromosome) or sex-linked (on a sex chromosome). 
 There are many single-gene diseases. Diseases such as phenylketonuria and 
cystic fibrosis are autosomal recessive, meaning the child inherited an allele from each 
parent that leads to the disease phenotype. Other diseases such as Huntington’s and 
myotonic dystrophy type 1 are autosomal dominant, meaning that one parent has the 
disease and it has been passed on to the child. The purpose of this project is to examine 
the aberrant alternative splicing that plays a key role in causing myotonic dystrophy 
type 1. 
Background: Myotonic Dystrophy Type 1 (DM1) and Muscleblindlike-1 (MBNL1) 
 Nearly 20 developmental and degenerative diseases caused by the expansion of 
unstable repeats are known today (8). Among these there are three classes of disorders: 
those that are caused by expansions of non-coding repeats and results in the loss of 
protein function, those that are causing by coding repeats and result in altered protein 
function and those that are caused by expansions of non-coding repeats which results in 
altered RNA function (Table 1). 
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Myotonic dystrophy type 1 is associated with a toxic gain-of-function by a CUG 
repeat expansion in the 3’ untranslated region (UTR) of the dystrophin myotonin 
protein kinase (DMPK) gene on chromosome 19 (9,10). Unaffected individuals have 
between 5 and 37 CTG repeats. Individuals with 50 repeats can start to exhibit 
symptoms. The severity of the disease is correlated with repeat length. With more than 
1500 repeats the result is often a severe congenital form. DM affects many different 
organ systems and has many major symptoms that include progressive skeletal wasting, 
impaired muscle relaxation, cardiac conduction defects resulting in arrhythmias, 
iridescent cataracts, insulin insensitivity, and others (11).  
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 The CUG repeats are proposed to be toxic primarily through their action 
sequestering the RNA binding protein, muscleblind-like 1 (MBNL1). This protein is 
important because it regulates alternative splicing of genes involved in development of 
skeletal muscle, the heart and the central nervous system. In DM1 the expanded CUG 
repeats co-localize with MBNL1 to form foci that make the active protein unavailable 
(12). Furthermore, with increased CUG repeats more MBNL1 is sequestered. A 
knockout of MBNL1 in mice produces a myotonic myopathy similar to DM1 along with 
DM1-like cataracts and cardiac disease, showing that MBNL1 sequestration plays a key 
role in DM1 (3). For example, the reduced concentrations of MBNL1 lead to the mis-
splicing of the chloride challen (CLCN1), which leads to the characteristic myotonia 
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(12). Other CUG binding proteins, CUG triplet repeat RNA-binding protein (CUGBP1) 
and ETR3-like factors (CELFs) have also been implicated in DM1 pathogenesis (8).  
 MBNL1 regulated splicing is dictated by the presence of RNA binding sites for 
this protein within the regulated pre-mRNAs. It was found that YGCY (where Y 
represents either U or C) is the minimal RNA binding site for MBNL1 (13). Most of the 
transcripts that are mis-spliced in DM1 include these motifs (Figure 4). The location of 
the YGCY motifs corresponds to whether MBNL1 causes inclusion or exclusion of the 
exon. If the site is located upstream of the exon then MBNL1 binding will generally 
lead to exon inclusion whereas when the YGCY motifs are located downstream of the 
exon, MBNL1 binding generally leads to exon inclusion (Figure 4, C). 
 
 Exon 5 of the MBNL1 pre-mRNA is mis-spliced in DM (14). Inclusion of the 
exon causes MBNL1 to be localized in the nucleus whereas isoforms of MBNL1 
lacking exon 5 are found both in the nucleus and the cytoplasm. The mis-splicing of 
MBNL1 was studied using a minigene that contained exons 4, 5 and 6 and introns 4 and 
5 of the MBNL1 gene (Figure 5). It was found that a 90-nucleotide region upstream of 
exon 5 containing a cluster of 10 MBNL1 binding sites was necessary in order to 
regulate inclusion of exon 5 by MBNL1 (Figure 6). Small deletions within the MBNL1 
response element were also made (Figure 6) but did not eradicate the ability of MBNL1 
to regulate exon 5 exclusion (Figure 6, B) (14).  
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In the absence of overexpressed MBNL1, percent exon 5 inclusion increased in 
all deletions as shown in Figure 7 (e.g. compare lane 1 to lane 2). When MBNL1 was 
overexpressed, inclusion of the exon decreased significantly and differences in activity 
between deletion constructs became evident (e.g. compare lane 5 to lane 7). Differences 
seen at high MBNL1 levels suggest that simply deleting one of these regions does not 
eliminate regulation, but that the degree of splicing regulation might be different.  
To fully understand how MBNL1 binding sites affect splicing, each deletion 
construct (Figure 7), must be examined over a range of MBNL1 concentrations in 
comparison with the splicing activity of the wild type MBNL1 minigene. Each deletion 
construct varies in the number of sites deleted and the location of the deletion or the 
distance from other sites that are important for splicing (i.e. splice sites). Examining 
each deletion construct at varying levels of MBNL1 would elucidate how these sites 
affect splicing decisions in the MBNL1 autoregulation splicing event. The possession of 
multiple sites could increase the probability of MBNL1 binding or these pre-mRNAs 
could require multiple MBNL1 binding events in order to block spliceosome regulation 
of exon 5. 
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Methodology: Overview 
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In order to study how MBNL1 affects splicing in myotonic dystrophy, a cell 
based splicing assay was used. Human embryonic kidney (HEK) 293 cells with the 
stably integrated MBNL1 gene were transfected with reporter minigenes of the events 
being studied. After transfection, a titration of doxycycline (dox) was added in order to 
induce expression of MBNL1. The titration of dox induced different amounts of 
MBNL1 protein to be made which mimicks how much free MBNL1 is available with 
different CUG length repeats. To measure splicing the RNA was extracted, reverse 
transcribed to DNA, PCR amplified, and quantified. 
Methodology: Stable MBNL1 expressing HEK293 cell line 
As discussed earlier, previous work that was done in order to understand 
MBNL1’s role in has used knockout models and over-expression models of MBNL1. 
These studies fail to examine the relationship between observed splicing and MBNL1 
concentration (which is affected by CUG repeat length). In order to directly investigate 
the effects of MBNL1, I will employ an inducible MBNL1 expression system to control 
MBNL1 protein levels to explore the dose-response effect on splicing of different 
MBNL1 deletion constructs.  
 The TRex Flp-In system (Invitrogen) was used to create a stable HEK293 cell 
line expressing a HA-tagged MBNL1. Levels of MBNL1 can be varied by titrating 
different concentrations of dox (Figure 8). 
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Methodology: Construction of Splicing Reporter Constructs (14) 
The MBNL-eGFP construct was obtained from the laboratory of Maury 
Swanson (University of Florida), and the DMPK CUG960 plasmid was obtained from the 
laboratory of Thomas Cooper (Baylor College of Medicine). The wild type MBNL1 
minigene was made by amplifying regions of the MBNL1 gene containing 51 
nucleotides from the 3’ -end of intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, and 
33 nucleotides of the 5’ -end of intron 6 from HeLa genomic DNA using PCR primers 
with unique restriction sites. The forward primer (5’-CCACAGGATCCGCTTCTT 
CTTCTTCATGTTGACTAAACCTCATG-3’) contained a BamHI site, and the reverse 
primer (5’ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCACCCC-
3’) contained a NotI site. The amplified genomic DNA was cut with BamHI and NotI, 
inserted into a pcDNA3 plasmid, and sequenced. 
The ∆90 minigene was made in two segments. The first segment was made 
using the forward primer 5’CCACAGGATCCGCTTCTTCTTCTTCATGTTGACT 
AAACCTCATG-3’ and the reverse primer 5’-GGCTTTCAATTGGTGCATTTTTG 
GGTAGGTGAGAAAAAACA-3’. The second segment was made using the forward 
primer 5’ –GGCTTTCAATTGAATTAAGACTCAGTCGGCTGTCAAATCAC-3’ and 
the reverse primer 5’-ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAA 
 
15  
ACCCCACCCC-3’. Segment 1 was cut with MfeI and BamHI, and segment 2 was cut 
with MfeI and NotI. Segments 1 and 2 were then ligated into a pcDNA3 plasmid and 
sequenced. 
The del1 minigene was made in two segments. The first segment was made 
using the forward primer 5’-CCACAGGATCCGCTTCTTCTTCTTCATGTTGACTA 
AACCTCATG-3’ and the reverse primer 5’-CATTAACATAAACAGCAAGCAG 
AGGGTGCATTTTTGGGTAGG-3’. The second segment was made using the forward 
primer 5’-CCTCTGCTTGCTGTTTATGTTAATGCGCTTGAACC-3’ and the reverse 
primer 5’ –ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAAACCCCACCCC-
3’. The two segments were ligated using standard PCR techniques, inserted into a 
pcDNA3 plasmid, and sequenced. 
 The del2, del3, del4, and del 5 minigenes were made using the PCR techniques 
described for the del1 minigene. All del minigenes used the same forward primer for the 
first segment and the same reverse primer for the second segment. The del2 minigene 
used the reverse primer 5’ –GGTTCAAGCGCATTAACATGCATCATGGGGCAGC-
3’ for the first segment and the forward primer 5’ –TGTTAATGCGCTTGAACCCCAC 
TGGCCATTGC-3’ for the second segment. The first segment of the del3 minigene was 
made using the reverse primer 5’-CATGATGGCAATGGGCCAGTGGTAAACAGCA 
AGCAGAGG- 3’, and the second segment was made using the forward primer 5’-
CCACTGGCCCATTGCCATCATGTGCTCGC-3’. The first segment of the del4 
minigene was made using the reverseprimer 5’ –
GCAGGCAGCGAGCACATGGGTTCAAGCGCATTAAC-3’. The second segment of 
the del4 minigene was made using the forward primer 5’ –CATGTGCTCGCTGC 
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CTGCTAATTAAGACTCAGTCGGC-3’ . The first segment of the del5 minigene was 
made using the reverse primer 5’ –GACAGCCGACTGAGTCTTAATTATGGC 
AATGGGCCAGTGG-3’. The second segment of the del5 minigene was made using 
the forward primer 5’-AATTAAGACTCAGTCGGCTGTCAAATCACTGAAGC 
GACCCC-3’. 
 The del3M minigene was made by site-directed mutagenesis of the wild type 
MBNL1 minigene. It was made using the forward primer 5'-AGCAAGCAGAGGT 
GCATCATG-3' and reverse primer 5'-GTTTATGTTAATCCCCTTGAACCCCAC-3'. 
This was amplified using standard PCR techniques, inserted into a pcDNA3 plasmid 
and sequenced.  
Methodology: Cell Culture and Transfection 
HEK293 cells were routinely cultured as a monolayer in DMEM media 
(Invitrogen) supplemented with 10% Fetal Bovine Serum (Gibco) at 37C under 5% 
CO2. Prior to transfection, cells were plated in 24-well plates at a density of 1.5 x 105 
cells/well. Cells were transfected 18–24 h later at ~ 80% confluency. In double 
transfection experiments, 250 ng of each plasmid was transfected into a single well; 
however, in single transfection experiments 250 ng of empty pcDNA3 vector was used 
to normalize plasmid concentration between wells. Dosing with dox was done 4-5 hours 
after transfection. Cells were harvested 18–24 h after transfection. RNA was isolated 
from the cell pellets using an RNeasy kit (QIAGEN) according to the manufacturer’s 
protocol. 
Methodology: In-vivo splicing assay 
All reporters were reverse transcribed using a pcDNA3 plasmid-specific 
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antisense primer, 5’ -AGCATTTAGGTGACACTATAGAATAGGG-3’. The -RT 
reactions were treated the same as the +RT reactions except that no SuperScript II was 
added to the -RT reactions. The cDNA from the RT reaction (2 µl) was subjected to 26 
rounds of PCR (within linear range) in a 20 µl reaction. PCR amplification for all splice 
products was done using the sense primer 5’ -GATCAAGGCTGCCCAATACCAG-3’ 
and the antisense primer 5’ –ATTCTTATGCGGCCGCCAGATTCATTTATTAAGAA 
ACCCCACCCC-3’. The PCR products were resolved on a 6% native polyacrylamide 
gel (40% 19:1 acrylamide:bisacrylamide) using SYBR Green (Applied Biosystems). 
The SYBR Green was diluted 10000X. Quantification of bands was done using the 
Alpha Imager HP Software from Alpha Innotech. Percent exon inclusion was calculated 
by dividing the amount of the band indicating inclusion by the total amount of splice 
product (bands indicating inclusion and exclusion). Background was taken from the 
space below the two bands. The splicing experiments shown in Figure 11 to 17 were 
done in triplicate. Averages with standard deviation are shown below gels in the figures. 
   
 
 
 
 
Results: Splicing assay of MBNL1 deletions constructs in HeLa and HEK293 cells 
 Previous work on these deletion constructs was performed in HeLa cells. The 
present study utilizes an inducible MBNL1 expression system in the HEK293 cell line. 
In order to understand how the previous studies compare to results from the new 
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system, splicing assays using both cell types were carried out. Differences in splicing 
activity helped to elucidate fundamental differences between the two cell lines. 
 
 Figure 9 shows the splicing of wild type MBNL1 and each of the five deletion 
constructs in HeLa cells. The first lane of each set includes a co-transfection with the 
CUG960 plasmid that mimics the disease state. The second of each set is without 
treatment and represent splicing under endogenous MBNL1 protein levels. The third 
lane shows splicing in the presence of overexpressed MBNL1 protein. The previous 
study did not assay splicing under disease state conditions. This study included a co-
transfection with CUG960 repeat plasmid in order to ascertain if differences existed at 
this state. As seen in Figure 9 exon 5 inclusion ranges from 94-99% indicating that the 
all constructs respond similarly in disease conditions. Under endogenous MBNL1 levels 
splicing activity of the constructs ranges from 60-94% exon inclusion indicating that the 
constructs behave differently when MBNL1 is at low levels. Thus we can see that 
deletion of binding sites (or systematic deletion of 16-19 nucleotide between the 
polypyrimidine tract and 3’-splice site) is having an effect on MBNL1’s ability to 
regulate exon 5 splicing. This becomes yet more apparent in the activity levels of 
splicing in the presence of overexpressed MBNL1. While exon 5 inclusion can be 
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driven down significantly, each construct responds differently and cannot be driven 
down to the same degree (ranging from 42% exon inclusion to 10%).  
 The same set of experiments was repeated using the inducible MBNL1 
expression system in the HEK293 cell line (Figure 10). In addition to the points that 
were assayed above, a high concentration of dox (20 ng/ml) was also included in order 
to find further differences between varying concentrations of MBNL1 protein. Just as in 
HeLa cells, the disease state does not vary much between different constructs indicating 
that at high levels of MBNL1 sequestration there is limited MBNL1 available for 
splicing. Differences between the wild type and deletion constructs become apparent at 
endogenous and high levels of MBNL1 just as they do in HeLa cells. Interestingly, for 
al six minigenes (wild type and the five mutants), overexpression of MBNL1-eGFP lead 
to a decrease in exon 5 inclusion compared to 20 ng/ml dox suggesting that 
overexpression via plasmid resulted in more MBNL1 protein. 
 
 It is important to note that though the level of exon 5 inclusion is significantly 
different in HeLa and HEK293 cells. In HeLa cells percent exon 5 inclusion can be 
pushed to as low as 10 % in the presence of overexpressed MBNL1, in HEK293 cells 
the level only drops to 36 %. If equal transfection efficiency occurred in both cell lines, 
the same amount of MBNL-eGFP was expressed, these results suggest that MBNL1 is 
less able to regulate exon 5 in HEK293 cells compared to HeLa cells. This is seen in all 
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constructs and under both endogenous and induced levels of MBNL1.  Presumably 
these differences are functions of the inherent differences between HeLa and HEK293 
cells. HeLa cells are a mature, adult cell line while HEK293 cells are embryonic. 
MBNL1, along with other splicing factors, are developmentally regulated. MBNL1 
levels are low at early stages and higher in adult cells. It is also possible that other 
factors work with MBNL1 to regulate this event and are at low levels or missing the 
HEK293 cells compared to the HeLa cells. 
Results: Dose-response behavior of the wild type MBNL1 minigene 
 In the MBNL1 autoregulation splicing event MBNL1 negatively regulates exon 
5 inclusion by binding upstream of the cassette exon where there is a clustering of 10 
YGCY motifs. The percent exon 5 inclusion decreases as MBNL1 protein levels 
increase (Figure 11). A significant increase in splicing activity is seen when comparing 
the disease state (Lane 1, Figure 11, C), and zero treatment or endogenous MBNL1 
levels (Lane 2, Figure 11, C). With 960 CUG repeats it can be assumed that there is no 
free MBNL1 in the nucleus. Endogenous levels, however, are enough to see a response 
from the MBNL1 minigene (80 % inclusion versus 98 % under the disease model). The 
response ranges from 39 percent exon 5 inclusion at high levels of dox / MBNL1 to 75 
percent exon 5 inclusion at the lowest level of MBNL1 for a 46 % change over the 
concentration range of dox tested. By 2.2 ng/ml dox the level of exon 5 inclusion had 
leveled off at the low 40 % range. 
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Results: Dose-response behavior of del1 
 The del1 mutant (Figure 12) has 18 nucleotides removed from the 5’ end of the 
90 nucleotide MBNL1 response element, which contains two MBNL1 binding sites. 
When treated with a titration of MBNL1 protein, del1 showed a different response than 
that of the wild type MBNL1 minigene. Endogenous levels of MBNL1 produce a 
change from the disease state in which 960 CUG repeats are co-transfected. The 
splicing activity of del1 ranges from 54 percent exon 5 inclusion at high concentrations 
of dox / MBNL1 to 82 percent exon 5 inclusion at the lowest concentration of dox / 
MBNL1. This range is reduced (28 % change) compared to wild type that had a 46 % 
change in exon 5 inclusion. In addition, more dox (3.2 ng/ml) is required to reach the 
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point at which the del1 mutant levels off (~55% exon 5 inclusion) compared to 2.2 
ng/ml for the wild type event. 
 
Results: Dose-response behavior of del2 
 Sixteen nucleotides were deleted in the del2 mutant construct. These 16 
nucleotides include two MBNL1 binding sites (Figure 13, A). Though the regulation of 
exon 5 inclusion in del2 responded to a titration of MBNL1, the response was different 
from that of the wild type MBNL1 minigene. Activity ranged from 61 percent exon 5 
inclusion at high levels of dox / MBNL1 to 82 percent at low levels of dox / MBNL1, 
which is significantly higher compared to wild type and modestly higher compared to 
del1. The slope of the dose-response curve also decreased along with the decrease in 
range of activity compared to wild type. 
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Results: Dose-response behavior of del3 
 In the del3 construct, 18 nucleotides have been deleted from the wild type 
MBNL1 minigene (Figure 14, A). These 18 nucleotides contain only one YGCY 
MBNL1 binding motif. Deletion of this site greatly decreases splicing activity 
compared to wild type and the other deletion mutants. Compared to the range of activity 
seen in splicing of the wild type splicing event (46 %), the range of del3 is significantly 
decreased (19 %). The percent exon 5 inclusion is shifted compared to wild type such 
that at the highest dox / MBNL1 concentration exon 5 is still included at 74 %. The 
slope in the linear portion of the curve is less steep compared to wild type as well. There 
is no change in splicing between the disease state (CUG960 plasmid co-transfection, 
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Lane 1 Figure 14, C.) and endogenous MBNL1 levels (zero treatment, Lane 2, Figure 
14, C), suggesting that the low level endogenous MBNL1 was not able to regulate del3 
at all. 
 
Results: Dose-response behavior of del4 
 Like del3, del4 also has one MBNL1 binding site in the 18 nucleotide deleted 
portion of the construct (Figure 15, A). Similar to the wild type MBNL1 minigene, del4 
shows an immediate difference in splicing activity between disease state (Lane 1, 
Figure 15, C) and endogenous MBNL1 levels (Lane 2, Figure 15, C) indicating del 4 is 
sensitive to endogenous MBNL1 protein. Interestingly, del4 had the lowest level of 
exon 5 inclusion at 32 % (wild type 39%). The range of activity for del4 (33%) is lower 
compared to wild type (46%) meaning the activity curve for del4 is shifted below wild 
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type. The slope for del4 is comparable to that of the wild type dose response curve. 
Although both del3 and del4 results in the removal of one MBNL1 binding site, only 
del3 had a profound effect on splicing activity while del4 had the most modest effect on 
MBNL1 activity. 
Results: Dose-response behavior of del5 
 Nineteen nucleotides were deleted in the del5 construct. This 19 nucleotide 
region contained four MBNL1 binding sites. Deletion of these four sites did not result 
in the loss of regulation of exon 5 inclusion by MBNL1 but did reduce the range of 
activity. Del5 has a similar reduction in range of activity (26 %) compared to the other 
mutants although not a reduced compared to del3 (Figure 16).  
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Results: Dose-response behavior of 3M 
 The most significant difference in splicing activity compared to wild type was 
seen in the del3 mutant as both the sensitivity (no regulation by endogenous MBNL1) 
and range of response were reduced. To determine if the single MBNL1 site or other 
aspects of del3 were important a site mutant of the del3 mutant was made (Figure 17, 
A). No nucleotides were deleted. Instead, the MBNL1 binding site within the 18 
nucleotide region of del3 was mutated (two guanosines were changed to cytosines). A 
dose response curve for this site mutant, 3M, was generated using the same splicing 
assay as described previously. The change in splicing activity for 3M ranged from 25 % 
(lowest dox / MBNL1) to 85 % exon 5 inclusion (highest dox / MBNL1). Although the 
3M splicing reporter was similar to del 3 (Figure 17, C), the range of splicing activity 
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for del 3 was less at 19 % compared to 25 % for 3M. Also, del3 only reduced exon 5 
inclusion to 74 % while 3M reduced exon 5 inclusion to 60 %. This result suggests that 
the YGCY site within the del3 region is major element of regulation and that additional 
aspects of this region (spacing of YCGY motifs and/or other sequence elements) likely 
modulate MBNL1 splicing regulation. 
 
 
 
Discussion: Overview 
 This study aimed to examine how the alternative splicing decisions in the 
MBNL1 pre-mRNA are dependent upon the number of MBNL1 binding sites. Inclusion 
of exon 5 is negatively regulated by MBNL1. The 3’-end of the flanking intron (intron 
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4) contains an ultraconserved region that is longer than 200 nucleotides within which a 
90 nucleotide region contains 10 YGCY MBNL1 binding sites that are necessary for 
exon 5 regulation by MBNL1 (14). Deletion constructs with binding sites deleted were 
examined over a range of MBNL1 protein concentrations. Though each deletion 
construct was still able to regulate exon 5 inclusion, this activity varied greatly showing 
that each region of the 90 nucleotide region was important and that the binding sites are 
not redundant. Del4 showed splicing activity similar to that of the wild type MBNL1 
minigene, while del3 exhibited splicing activity most different from wild type.  
 
 
 
Discussion: Sensitivities  
 Each deletion construct exhibited a different dose response to MBNL1 as seen in 
Figures (11-17). The sensitivity of each construct to MBNL1 was defined as the change 
in splicing (ΔSC) under disease conditions (co-transfection with CUG960) to 
endogenous MBNL1 levels (zero dox). Table 2 shows the ΔSC for the wild type 
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minigene and the six mutants. While ΔSC for wild type was 18 %, this was not the most 
sensitive construct. The ΔSC for del 4 was 28% indicating that at endogenous MBNL1 
levels, splicing decisions are being shifted farther away from inclusion than in wild 
type. Del3 was the least sensitive to MBNL1 at endogenous levels. The 3M mutation, 
modestly increased the sensitivity (5%). Since there was only a small change in the 
sensitivity of 3M, this indicates that the MBNL1 binding site in this region is important 
for regulation but that other aspects of this region are also important when regulating 
splicing decisions. 
Discussion: Dose-response behavior of constructs to dox titration 
 Table 1 shows the range of response of each minigene to dox / MBNL1 titration 
(ΔPSI) and the slope of each curve. While the ΔSC and ΔPSI provide information about 
sensitivity and range of response respectively, the slope provides information about the 
different in the mechanism by which each deletion construct is regulating splicing.  
ΔPSI for wild type was 46 % which was the largest range among the seven 
minigenes and has a slope of -3.5. Though del4 exhibited higher sensitivity to MBNL1 
than the wild type minigene, the ΔPSI for del4 is 33 % which is smaller than the wild 
type range. This is because at 0.5 ng/ml of dox, exon 5 inclusion is ~65% whereas for 
wild type exon 5 inclusion is ~75%. Thus del4 is already closer to the final percentage 
of exon 5 inclusion than wild type is. Also, the range being capture is smaller because 
the curve is shifted to the left (Figure 15). Del3 had the smallest range (ΔPSI = 19 %) 
compared to wild type and the most different slope (-2.0). The 3M site mutant had an 
slightly increased range (ΔPSI = 25 %) indicating again that the YGCY motif, while 
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being an important regulatory event, there are other aspects of the del3 region that are 
important for splicing regulation. 
Discussion: Binding site number and distance from 3’-splice site 
 Del3, which showed the largest deviation from wild type MBNL1 behavior 
(Table 2), contained the deletion of a single YGCY binding motif and was in the center 
of the 90 nucleotide regulatory element. In order to understand whether this deletion has 
such a profound effect on splicing activity due to the deletion of the site or deletion of 
the 18 nucleotides which affected the distance of binding sites from the 3’-splice site, 
the 3M mutant was assayed. It was found to have an activity similar to that of the del3 
mutant though there were some differences in activity (both the sensitivity and range of 
response increased slightly). This indicates that both the MBNL1 binding site contained 
within the region of del3 and the spacing of YGCY motifs in is important for regulation.  
Furthermore, the number of missing potential MBNL1 binding sites does not 
correlate with reduced range of activity because if this simple correlation existed we 
would have expected del5 (four for del 5) to display the largest reduction in range of 
activity. The deletion of one site in one specific location (del3) affects splicing more 
than the deletion of multiple sites (del5) (Table 2). Del5 includes a cluster of four 
binding sites that is closest in the 90 nucleotide regulatory element to the 3’-splice site. 
Yet their removal does not have as dramatic of an effect as del3, which includes only 
one site and is farther from the 3’-splice site. If the binding of MBNL1 at the sites 
upstream of the 3’-splice site was necessary in order to block spliceosome activity, del5 
would presumably effect splicing activity more.  In the same way if multiple sites were 
needed in order to promote MBNL1 binding then the deletion constructs with more than 
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just one MBNL1 binding site would show decreased splicing activity. Neither 
hypothesized mechanism fully explains how MBNL1 is affecting splicing since the 
deletion of a single site in del3 greatly increases exon 5 inclusion. Del4, however, 
which is also a deletion that contains only one MBNL1 binding site, behaves as the wild 
type MBNL1 minigene does. This suggests that the mechanism of MBNL1’s negative 
regulation of exon 5 inclusion is more complicated than multiple MBNL1 binding 
events upstream of exon 5. The data suggest that the different MBNL1 binding sites are 
neither equivalent nor redundant, but that each one contributes to splicing activity to 
some degree.  
It is possible that other splicing factors have binding sites within this regulatory 
regions and the deletion of their binding sites is what is affecting splicing activity levels 
in the deletion constructs. Further mutational and knockdown studies could ascertain 
what other splicing factors are affecting the splicing events that are regulated by 
MBNL1. 
 
 
Future Directions 
 This assay has provided much more information about each construct and how 
the different regions contribute to splicing than a simple overexpression assay. In order 
to further study the mechanism behind MBNL1 promotion of exon 5 exclusion in the 
wild type MBNL1 pre-mRNA, more mutational analysis should be performed using this 
assay. It would be informative to know which of the 10 binding sites are sufficient for 
regulation. This could be done via further mutational analysis. The 90 nucleotide region 
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could also be replaced with repeating YGCY repeats in order to see if splicing activity 
can be increased beyond that of the wild type MBNL1 minigene.   
 In order to further characterize what makes del3 (and 3M) so different from the 
rest of the deletions, it would be useful to shift the location of the YGCY site within the 
18 nucleotides of del3. The region of del3 could also be placed in a different part of the 
90 nucleotide regulatory region in order to determine how distance from the 3’splice 
site of this site affects splicing. 
 Del4 is another interesting construct in that it is more sensitive to endogenous 
MBNL1 than the wild type minigene. Moving the del4 region to a different location 
within the 90 nucleotide regulatory element would help determine how the spacing of 
this YGCY motif affects splicing.  
 Furthermore, mutations in which a YGCY binding region from a different 
minigene regulated by MBNL1 is inserted upstream of the MBNL1 exon 5 regulation 
event could show if the change in splicing can be rescued. 
Knocking down other splicing factors could also show what splicing factors are 
necessary besides MBNL1 and define what are available in HEK293 cells. 
 
 
 
 
 
 
 
 
33  
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
1. Wahl, M.C., Will, C.L., Luhrmann, R. (2009) Cell 136, 701-718. 
2. Hallegger M, Llorian M, and Smith CWJ. (2010) FEBS Journal 277:856-886. 
3. Wang, et. al. (2008) Nature 456:470-476.  
4. Murray, J.I., Voelker, R.B., Henschied, K.L., Warf, M.B., Berglund, J.A. (2008) 
Genome  
    Biol. 9(6), R97. 
5. Hoskins, A.A., Moore, M.J. Trends Biochem Sci. (2012) 37(5):179-188. 
6. Nilsen, T.W. (2003) Bioessays 25:1147-1149. 
7. Sammeth M, Fossaic S, Guigo R. (2008) PLoS Comput Bio 4:8. 
 
34  
8. Gatchel, J.R., Zoghbi, H.Y. (2005). Nature Reviews. 6, 743-755. 
9. Ranum, L. P., and Day, J. W. (2004) Am. J. Hum. Genet. 74, 793– 804 
10. Ranum, L. P., and Cooper, T. A. (2006) Annu. Rev. Neurosci. 29, 259 –277 
 
11. Osborne, R. J., and Thornton, C. A. (2006) Hum. Mol. Genet. 15, R162–R169 J  
12. Fardaei, M., Larkin, K., Brook, J. D., and Hamshere, M. G. (2001) Nucleic Acids 
Res.  
 
    29, 2766 –27711  
  
13. Charlet-B, N., Savkur, R. S., Singh, G., Philips, A. V., Grice, E. A., and Cooper, T. 
A.      
    (2002) Mol. Cell 10, 45–53 
14. Goers, E. S., Purcell, J., Voelker, R. B., Gates, D. P., and Berglund, J. A. (2010) 
Nucleic Acids Res. 38, 2467–2484 
15. Terenzi, F., and Ladd, A. N. (2010) RNA Biol. 7, 43–55 
16. Gates D.P., Coonrod L.A., and Berglund J.A. (2011). J Biol Chem 286: 34224-
34233 
17. Berejano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W.J., Mattick, J.S.,  
      Haussley, D. (2004) Science. 304, 1321-1325. 
 
